SGS518: Preliminary Phase IIa data

Preliminary data from a dose-escalation, placebo-controlled, U.S. Phase IIa trial in 20 schizophrenic patients showed that 14 days of treatment with 240 mg SGS518 was well tolerated. The high-dose (12...